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  Zinc released from excited glutamatergic neurons accelerates amyloid β (Aβ ) aggregation, under-
scoring the therapeutic potential of zinc chelation for the treatment of Alzheimer’s disease (AD). Zinc 
can also alter Aβ concentration by affecting its degradation. In order to elucidate the possible role 
of zinc influx in secretase-processed Aβ production, SH-SY5Y cells stably expressing amyloid precursor 
protein (APP) were treated with pyrrolidine dithiocarbamate (PDTC), a zinc ionophore, and the 
resultant changes in APP processing were examined. PDTC decreased Aβ40 and Aβ42 concentrations 
in culture media bathing APP-expressing SH-SY5Y cells. Measuring the levels of a series of C-terminal 
APP fragments generated by enzymatic cutting at different APP-cleavage sites showed that both β- 
and α-cleavage of APP were inhibited by zinc influx. PDTC also interfered with the maturation of 
APP. PDTC, however, paradoxically increased the intracellular levels of Aβ40. These results indicate 
that inhibition of secretase-mediated APP cleavage accounts -at least in part- for zinc inhibition of 
Aβ secretion.
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INTRODUCTION
  Alzheimer’s disease (AD) is the most common cause of 
dementia. The pathologic hallmarks of AD are neuro-
fibrillary tangles and senile plaques, the main components 
of which are tau (a microtubule-associated protein) and 
amyloid beta peptide (Aβ) respectively (Glenner and Wong, 
1984; Kosik et al., 1986; Selkoe, 1999). Aβ is produced by 
the sequential cleavage of amyloid precursor protein (APP) 
by β- and γ-secretases. Alternatively, APP can be cleaved 
by α-secretase at a position between the β- and γ-cleavage 
points, resulting in the production of non-amyloidogenic 
sAPPα (Vassar and Citron, 2000). APP can also be subject 
to posttranslational modifications including glycosylation, 
sulfation, and phosphorylation. The immature form of APP 
is N-glycosylated and the mature form is N- and O-glycosy-
lated (Weidemann et al., 1989). This maturation is consid-
ered to be a prerequisite for Aβ production and leads to 
an increase in molecular mass of 19∼22 kilodaltons (kD) 
(Weidemann et al., 1989; Pahlsson et al., 1992; Tomita et 
al., 1998). Any factors that accelerate Aβ aggregation can 
be precipitating factors in the development of AD, including 
enhanced production of Aβ, a decreased Aβ clearance rate 
and the promotion of Aβ precipitation (Bush et al., 1994).
  Zinc is concentrated in presynaptic vesicles containing 
the neurotransmitter glutamate and co-released into the 
synaptic cleft (Frederickson, 1989). The local concentration 
of zinc spikes to hundreds of micromoles upon excitotoxic 
events including ischemia, seizure, and trauma (Frederickson, 
1989). The synaptic zinc released in excitotoxic conditions 
translocates into postsynaptic neurons, thereby causing 
neuronal damage (Choi and Koh, 1998).
  The role of zinc in the pathogenesis of AD has been sug-
gested by many studies. Bush et al. (1984) reported that 
zinc precipitates Aβ peptide (Bush et al., 1994). Clioquinol, 
which chelates zinc and copper ions, decreases Aβ accumu-
lation and enhances memory functions in transgenic mouse 
models of AD (Cherny et al., 2001). ZnT3(−/−) mice that 
fail to accumulate zinc in glutamate-containing synaptic 
vesicles show a markedly reduced number of senile plaques 
compared with ZnT3(＋/＋) mice (Lee et al., 2002). These 
reports have focused on zinc-mediated acceleration of Aβ 
aggregation in the extracellular space. On the other hand, 
it has also been reported that zinc can modulate the ex-
tracellular levels of Aβ. Zinc activation of matrix metal-
loproteases (MMPs) has been suggested as one of the under-
lying mechanisms for accelerated clearance of secreted 
monomeric Aβ, as MMPs contribute to Aβ destruction 
(White et al., 2006). However, whether APP processing can 
be regulated by zinc as well as the effect of zinc on intra-
cellular Aβ levels have yet to be tested. In this study, we 
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show that pyrrolidine dithiocarbamate (PDTC), a zinc ion-
ophore, inhibits secretase-executed APP processing path-
ways and causes intracellular Aβ accumulation.
METHODS
Construction of plasmids
  The coding region of human APP695 in cDNA prepared 
from HEK293 cells was amplified by PCR using the following 
primers: 5’-CCCAAGCTTGCCACCATGCTGCCCGGTTTGG-3’ 
and 5’-GCTCTAGACTAGTTCTGCATCTGCTCAAAG-3’. The 
amplified DNA fragment was digested, subcloned into 
pcDNA3 (Invitrogen, Carlsbad, CA, USA) at HindIII/XbaI 
sites and named pcDNA3-hAPP695. The Swedish mutant 
form (K670N/M671L) pcDNA3-hAPP695swe, a two base 
pair transversion (GA to TC) of hAPP695, was made by 
site-directed mutagenesis using the primers 5’-AGGAGAT-
CTCTGAAGTGAATCTGGATGCAGAATTCCGACA-3’ and 
5’-TGTCGGAATTCTGCATCCAGATTCACTTCAGAGATCT
CCT-3’ (the nucleotides underlined were changed).
Cell culture
  Cell culture media, fetal bovine serum (FBS), and anti-
biotics were purchased from Invitrogen (Carlsbad, CA, 
USA). SH-SY5Y cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% FBS, 100-U/ml 
penicillin, and 100-μg/ml streptomycin at 37oC in 5% 
CO2/95% air. The SH-SY5Y cells were lipotransfected with 
pcDNA3-hAPP695 or pcDNA3-hAPP695swe and 500-μg/ml 
geneticin was used for three weeks to select stable clones, 
named SH-SY5Y-wt and SH-SY5Y-swe respectively. The 
polyclonal stable cell lines were maintained with 250-μg/ml 
geneticin.
Sandwich ELISA
  For the measurement of secreted Aβ40 and Aβ42 as 
well as intracellular Aβ40, SY5Y-wt or SY5Y-swe cells 
were plated on 60-mm culture dishes at 70% confluence. 
After 24 h of incubation, culture media was changed with 
2 ml of fresh media and incubated for 4 h either with or 
without drugs. In case of serum deprivation, DMEM was 
supplemented with 0.2-mg/ml bovine serum albumin (BSA) 
(Sigma, St. Louis, MO, USA). The conditioned media was 
supplemented with 5-mM EDTA (ethylenediaminetetraace-
tate) and 1-mM AEBSF (4-(2-aminoethyl)-benzenesulfonyl 
fluoride) and briefly centrifuged for removal of cell debris. 
Cells were collected by scraping and lysed with phosphate 
buffered saline (PBS) containing 1% Triton X-100, 
Complete protease inhibitor cocktail (Roche Applied 
Sciences, Indianapolis, IN, USA), and 10-μM DAPT (N-[N- 
(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl es-
ter), a γ-secretase inhibitor (EMB Chemicals, San Diego, 
CA, USA). The levels of Aβ40 and Aβ42 in the conditioned 
media and cell lysates were measured by sandwich en-
zyme-linked immunosorbent assay (ELISA) according to 
the manufacturer’s instruction (IBL, Takasaki-Shi, Japan).
Immunoprecipitation and immunoblotting
  For the immunoblot assay of Aβ40, SH-SY5Y-wt cells 
were washed twice with PBS containing 1.8-mM Ca2＋ and 
incubated in DMEM supplemented with 0.2-mg/ml BSA − 
the concentration of albumin in human cerebrospinal fluid 
− for 4 h. The secreted proteins from SH-SY5Y-wt cells 
in the conditioned media were precipitated by adding up 
to 10% (w/v) trichloroacetic acid (TCA) and centrifuging at 
2,500 g for 1 h at 4oC. The protein pellets were washed 
twice with 100% acetone and dried. The proteins were dis-
solved in TNT lysis buffer (50-mM Tris pH 8.0, 100-mM 
NaCl, 1% Triton X-100, Complete protease inhibitor cock-
tail) and immunoprecipitated with Aβ40 antibody (Invitro-
gen, Carlsbad, CA, USA). The immunoprecipitated proteins 
were electrophoresed in 16.5% Tris-Tricine gels before be-
ing transferred to a nitrocellulose membrane (Whatman, 
Florham Park, NJ, USA) which was then boiled in PBS for 
5 min for fixation before being probed with the same 
antibody.
  To measure C99 and C83, carboxy-terminal fragments of 
APP cleaved by β- and α-secretase respectively, cell lysates 
supplemented with 10-μM DAPT were immunoprecipitated 
with rat anti-APP C-terminus antibody. This antibody was 
raised against the 561∼676 residue of human APP and sep-
arated in 16.5% Tris-Tricine gel for immunoblotting with 
rabbit anti-APP C-terminus antibody (IBL, Takasaki-Shi, 
Japan).
  For sAPPα and full length APP (holoAPP), proteins in 
culture media or cell lysates were separated by 7% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE) and transferred to a nitrocellulose membrane. The 
membrane was probed with monoclonal anti-Aβ(1∼17) anti-
body 6E10 (Sigma, St. Louis, MO, USA) for sAPPα and with 
rabbit anti-APP C-terminus antibody (IBL, Takasaki-Shi, 
Japan) for holoAPP. 
RESULTS
Effect of PDTC on secreted Aβ40 and Aβ42 levels in 
culture media
  To investigate the effects of zinc influx on Aβ levels in 
SH-SY5Y-wt conditioned culture media, PDTC was ad-
ministered as a zinc ionophore into media containing 10% 
FBS (Kim et al., 1999a; Kim et al., 1999b). Sandwich 
ELISA for Aβ40 showed that the treatment of 0-, 20-, 50-, 
and 100-μM PDTC for 4 h decreased Aβ40 levels in a 
dose-dependent manner (Fig. 1A). At 100 μM, PDTC reduced 
Aβ40 concentration in the culture media by 29±7.2%. The 
concentration of Aβ42, one of the two most common iso-
forms of Aβ, also decreased to a level similar to the level 
of Aβ40 (Fig. 1B).
Mechanism of PDTC action
  To confirm the zinc-ionophore action of PDTC, media was 
pretreated with EDTA for 30 min before PDTC treatment. 
EDTA, which sequesters divalent and trivalent metal ions, 
restored Aβ40 reduction by PDTC, indicating that the 
PDTC action was due to a metal ionophore (Fig. 2A). PDTC 
is not only a zinc ionophore, but also a copper ionophore 
in certain conditions (Meyer et al., 1993; Chinery et al., 
1997; Verhaegh et al., 1997; Iseki et al., 2000). To determine 
which metal is involved in the PDTC reduction of Aβ, the 
serum-depleted culture media bathing SH-SY5Y-wt cells 
was supplemented with zinc sulfate and copper sulfate, 1.5μM 
each, and PDTC was co-administered. Neither PDTC single 
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 A                    B
Fig. 1. PDTC decreases Aβ levels in
the conditioned media. PDTC was 
added to SH-SY5Y-wt cells at the 
concentration indicated for 4 h. Aβ40
(A) and Aβ42 (B) in the conditioned
media were quantified by sandwich 
ELISA. Bars represent the means±
S.D. of three independent experi-
ments. Control represents no drug 
treatment. Statistical significance 
was represented as *(p＜0.05).
   A   B
  C
Fig. 2. Zinc is required for PDTC action. Aβ40 levels in the conditioned media from SH-SY5Y-wt cells were measured by sandwich ELISA
(A and B) or by TCA precipitation followed by combined immunoprecipitation and immunoblot assays with Aβ40 antibody (C). (A) 
SH-SY5Y-wt cells were incubated with or without 100-μM PDTC and/or 10-μM EDTA for 4 h. (B) Serum-deprived SH-SY5Y-wt cells
were treated as follows: control, 100-μM PDTC, 100-μM PDTC with 1.5-μM ZnSO4 or 1.5-μM CuSO4, 1.5-μM ZnSO4, and 150-μM ZnSO4
for 4 h. (C) The serum-free conditioned media from SH-SY5Y-wt cells treated with or without PDTC plus 1.5-μM zinc were concentrated
by TCA precipitation for Aβ40 assay (see methods). Bars represent the mean±S.D. of three different experiments. Control represents no
drug treatment. Statistical significance was represented as *(p＜0.05).
treatment nor copper treatment with PDTC decreased Aβ
40 levels. In contrast, PDTC-zinc co-treatment induced robust 
reduction in Aβ40 levels (Fig. 2B). This result was sup-
ported by an additional experiment: proteins in the culture 
media were precipitated with TCA and subjected to combined 
immunoprecipitation and immunoblot assays for Aβ40 
(Fig. 2C), demonstrating that PDTC plus 1.5-μM zinc de-
creased the band intensity representing Aβ40. 
Furthermore, treatment of 150-μM zinc sulfate alone de-
creased Aβ40 levels in the media (Fig. 2B). These results 
indicate that PDTC-facilitated zinc influx into SH-SY5Y 
cells reduced secreted Aβ40 levels in the culture media.
Effects of PDTC on the levels of APP metabolites
  To understand the underlying mechanisms of zinc reduc-
tion in intracellular Aβ40 levels, changes in concentration 
of APP metabolites produced by distinct secretase-mediated 
cleavage of APP were analyzed after treatment with PDTC. 
The amino-terminal fragment generated by α-cleavage, 
sAPPα, was assayed by immunoblot using the anti-Aβ
(1∼17) antibody. C-terminal fragment (CTF) α (C83) and 
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Fig. 3. APP processing by β- and α-secretase is inhibited by PDTC. The cell lysates (A) or conditioned media (B) of SH-SY5Y-wt cells
treated with or without 100-μM PDTC were analyzed by immunoblot assay (B) or combined immunoprecipitation-immunoblot assay (A)
(see methods). The amounts of C99 and C83 detected in immunoblot assays with APP C-terminus antibodies were semi-quantified with
densitometry. A monoclonal 6E10 antibody (against a.a. 1∼17 of human Aβ) was used for the sAPPα assay. Bars represent the means±S.D.
of two or three independent experiments. Control represents no drug treatment. Mature APP is represented as mAPP; immature APP,
imAPP. Statistical significance was represented as *(p＜0.05).
Fig. 4. PDTC increases intracellular Aβ40. SH-SY5Y-swe cells 
were incubated with or without 100-μM PDTC for 4 h and then
scraped, pelleted and lysed. Aβ40 in the cell lysates was assayed
by sandwich ELISA. Bars represent the mean±S.D. of three 
independent experiments. Control represents no drug treatment. 
Statistical significance was represented as *(p＜0.05).
CTFβ (C99), a longer CTF form generated by β-cleavage, 
were enriched by immunoprecipitation with rat anti-APP 
C-terminus antibody and resolved by SDS-PAGE for de-
tection with rabbit anti-APP C-terminus antibody. PDTC 
decreased the levels of both C99 and C83 in cell lysates 
and also the level of sAPPα in the media (Fig. 3). These 
results suggested that zinc influx inhibited secretase-medi-
ated Aβ40 processing. Next, PDTC-induced changes in in-
tracellular Aβ40 levels in cell lysates were examined. We 
used SH-SY5Y-swe instead of SH-SY5Y-wt cells because 
the Aβ level in SH-SY5Y-wt cells was too low to be 
detected. APP is also more susceptible to β-secretase in 
SH-SY5Y-swe cells. Interestingly, the Aβ40 level in the 
SH-SY5Y-swe cell lysates, which was assayed by sandwich 
ELISA, increased following PDTC treatment (Fig. 4). 
Inhibition of APP maturation by PDTC
  Intriguingly, the electrophoretic mobility of sAPPα was 
also changed by PDTC (Fig. 3B), suggesting a potential 
PDTC effect on posttranslational modifications of APP. 
Thus, gel mobility of full-length APP (holoAPP) was exam-
ined following PDTC treatment. APP is known to be de-
tected as multiple bands on immunoblotting when labeled 
with an APP C-terminus antibody. The immature form has 
been reported as 91∼106 kD and the mature form as 20 
kD larger (Weidemann et al., 1989; Caporaso et al., 1992; 
Pahlsson et al., 1992). Tomita et al. (1998) reported im-
mature APP as two bands, results consistent with our find-
ings (Fig. 5A). PDTC did not affect the level of holoAPP 
in the cell lysates (Fig. 5A, B). It did, however, inhibit APP 
maturation, as demonstrated by the decrease in the mature 
APP to immature APP ratio (Fig. 5C). An actin immuno-
blotting was used as a loading control.
DISCUSSION
  In this study, we have shown for the first time that 
PDTC-facilitated influx of zinc into cells stably expressing 
hAPP695 inhibits not only APP processing by both α- and 
β-secretase but also APP maturation. An intracellular 
increase in zinc concentration is required for APP process-
ing because although low concentrations of zinc did not in-
duce APP processing suppression, co-treatment with PDTC − 
a zinc ionophore − efficiently suppressed α- and β-secre-
tase-dependent APP cleavage. This inhibitory effect of in-
tracellular zinc on amyloid production is in striking con-
trast to the seemingly opposite role of extracellular zinc in 
precipitating Aβ aggregation, a process which leads to the 
development of amyloid plaques. Until now, relatively little 
was known about the role of intracellular zinc in Aβ 
pathology. To date, the only report available found that zinc 
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  A B
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Fig. 5. Maturation of APP is 
inhibited by PDTC. Cell lysates of 
SH-SY5Y-wt cells treated with or 
without 100-μM PDTC for 4 h were
separated in 7% SDS-PAGE. (A) APP
was immunoblotted with APP C-ter-
minus antibody. (B) Quantitative an-
alysis of the holoAPP bands (mature
form＋immature form). Amount of 
holoAPP was normalized to actin 
levels. (C) The maturation degree of
APP was shown by the percentage of
mAPP to imAPP. Bars represent the 
mean±S.D. of three independent ex-
periments. Control represents no drug
treatment. Statistical significance was
represented as *(p＜0.05).
recruited into the intracellular space by the metal-chelator 
clioquinol culminates in a reduction of Aβ levels by activa-
tion of MMPs capable of cleaving Aβ at multiple sites 
(White et al., 2006). Clioquinol, like PDTC, increases the 
intracellular levels of copper and zinc, important biometals 
in the development of AD (Caragounis et al., 2007). The 
proposed modes of action of these two compounds differ in 
terms of their proposed recruited-metal targets. Our study, 
however, still supports the general hypotheses that intra-
cellular biometal concentration is important for regulating 
the secretion of Aβ in vitro and that metal-ligands might 
have therapeutic potential for AD in vivo.
  Glycosylation of APP potentially plays an important role 
in the secretion of Aβ and other APP derivatives. Glycosyl-
ation inhibitors diminish sAPPα secretion in Chinese ham-
ster ovary (CHO) cells expressing hAPP695-wt (Pahlsson 
and Spitalnik, 1996). Protein kinase A (PKA) inhibitors de-
crease mature APP and lead to an accumulation of im-
mature APP, processes associated with reduced Aβ pro-
duction (Su et al., 2003). Tomita et al. demonstrated that 
the aberration of O-glycosylation of APP by certain muta-
tions leads to a reduction of C83 in cell lysates and the 
suppression of Aβ secretion (Tomita et al., 1998). Zinc in-
hibition of APP maturation may also account for the de-
crease in Aβ secretion because α-, β-, and γ-secretase 
cleavage of APP occurs only after O-glycosylation of APP. 
Moreover, it is likely that zinc affects certain earlier proc-
esses in the APP secretion pathway rather than affecting 
the secretases themselves, because zinc did not show any 
selective action on either α- or β-cleavage of APP.
  Another important finding of this study is that PDTC-fa-
cilitated zinc influx causes an accumulation of intracellular 
Aβ in SH-SY5Y cells. In astrocytes of patients with Down 
syndrome, secretion of sAPPα and Aβ are decreased, but 
intracellular Aβ accumulates, which might be due to mi-
tochondrial dysfunction in Down syndrome (Busciglio et al., 
2002). Reynolds and his colleagues also demonstrated that 
zinc could be a mitochondrial toxin in neurodegeneration 
(Dineley et al., 2003). Considering these reports, mitochon-
drial damage caused by PDTC-facilitated influx of zinc 
might lead to accumulation of Aβ in SH-SY5Y cells. As 
described previously, an increase in intracellular zinc can 
activate MMPs and this might cause degradation of intra-
cellular Aβ. On the other hand, intracellular free zinc 
might interact directly with Aβ as well, thereby affecting 
Aβ stability. The net effect of zinc-Aβ interactions in our 
study is the accumulation of Aβ in SH-SY5Y cells, suggest-
ing that, at least at intracellular sites, zinc activation of 
MMPs does not play a major role in determining Aβ levels. 
The reason for the discrepancy in the effect of zinc-MMP 
interaction might be due to different experimental con-
ditions such as the presence of 10% FBS which has much 
anti-protease activity or different cell systems we used.
  In this report, zinc influx reduces neurotoxic Aβ 
secretion. This begs the complicated question of whether 
zinc is a protective factor for Alzheimer’s disease. Some re-
ports have shown that the zinc content in the brains of pa-
tients with AD is somewhat decreased (Wenstrup et al., 
1990; Corrigan et al., 1993). Zinc is also one of the im-
portant biometals that promotes the extracellular for-
mation of amyloid plaque. Thus, limited by the current 
paucity of evidence, it is difficult to predict the role of zinc 
in protection from or promotion of amyloid pathology. 
However, the accumulation of intracellular Aβ by zinc in-
flux might still contribute to the development of AD.
  Oligomerization of Aβ begins intracellularly (Walsh et 
al., 2000), suggesting that zinc-induced Aβ accumulation 
in cells might accelerate its oligomer formation. Synaptic 
dysfunction and neuronal death are produced by Aβ 
oligomers (Lambert et al., 1998; Walsh et al., 2002), which 
become a core for further oligomerization and aggregation. 
Although elevated levels of intracellular zinc are beneficial 
in decreasing the secretion of Aβ, accumulated Aβ (or pos-
sibly Aβ oligomerized by zinc) might be released once zinc 
concentration returns to the basal level, resulting in aggre-
gation of Aβ. Moreover, the secreted form of APP, sAPPα, 
has neuroprotective and memory enhancing effects (Furukawa 
et al., 1996; Meziane et al., 1998), leading to the postulation 
that zinc influx is detrimental to AD patients due to the 
suppression of sAPPα secretion. It remains to be determined 
200 J Lee, et al
whether zinc influx can precipitate Aβ oligomerization and 
which zinc-provoked events are most relevant and im-
portant in AD pathogenesis.
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